ANXA5 and pancreatic neoplasm: Moreover, CCK‐8, caspase 3 activity, and Annexin V/PE assays demonstrated that FBP1 knockdown resulted in pancreatic cancer cell resistance to Olaparib in vitro (Fig. 1C–F).